Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study of RGN-259 for Neurotrophic Keratopathy

Next Previous
Search
Trial Profile

Phase 3 study of RGN-259 for Neurotrophic Keratopathy

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Keratitis; Neurotrophic keratopathy
  • Focus Registrational; Therapeutic Use
  • Acronyms SEER-3
  • Sponsors ReGenTree

    • Most Recent Events

    • 13 Apr 2023 According to a RegeneRx Biopharmaceuticals media release, ReGenTree plans to recruit more than 30 clinical institutions in the U.S. to accelerate patient recruitment.
    • 03 Jan 2023 According to a RegeneRx Biopharmaceuticals media release, the first patient expected to be entered later this month
    • 27 Sep 2022 According to a RegeneRx Biopharmaceuticals media release, SEER-3 clinical trial, will be conducted simultaneously in the U.S. and Europe, the study site selection process is ongoing by ReGenTree among 80 candidate sites in six European countries, and preparation of applications to be filed through CTIS (Clinical Trials Information System) is also underway.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top